
IO Biotech (NASDAQ:IOBT) on Monday released topline results from the pivotal Phase 3 trial of its investigational, immune-modulatory, off-the-shelf therapeutic cancer vaccine, Cylembio (imsapepimut and etimupepimut, adjuvanted).
The trial evaluated Cylembio in combination with Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab), vs. pembrolizumab alone as a first-line treatment for unresectable or metastatic (advanced) melanoma.